{"name":"Dermavant Sciences GmbH","slug":"dermavant-sciences-gmbh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Cerdulatinib 0.37% gel","genericName":"Cerdulatinib 0.37% gel","slug":"cerdulatinib-0-37-gel","indication":"Atopic dermatitis (topical)","status":"phase_2"}]}],"pipeline":[{"name":"Cerdulatinib 0.37% gel","genericName":"Cerdulatinib 0.37% gel","slug":"cerdulatinib-0-37-gel","phase":"phase_2","mechanism":"Cerdulatinib is a dual JAK1/SYK inhibitor that suppresses inflammatory signaling pathways in immune cells to reduce skin inflammation.","indications":["Atopic dermatitis (topical)","Alopecia areata (topical)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQY2oyMmJqb2hBNTRwM2ZyREtGaHFIQlJxekJGakJjNTA2ZV9HcnhSc01QZkU4aXFwcm9WeF84d2tTV0h6MldCdnhOV0FmSlJaamh4NHdxUmJzYXhVQV9Wem1zWEg4MWtnMmIxNkxOc1B3WEN3VGNQd2FQbFlKbkF6d09ZQlctTm9fekxGWGlNYzA2UzhMTnY5TjB1eVJsZ28tRFE?oc=5","date":"2026-04-07","type":"pipeline","source":"openPR.com","summary":"Plaque Psoriasis Market Size is Predicted to See Upsurge Through 2034, Highlights DelveInsight - openPR.com","headline":"Plaque Psoriasis Market Size is Predicted to See Upsurge Through 2034, Highlights DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQU3NGOGJkLXNCX2VVN1d1al96c3dNMnhCRkgtaktKUGpZT2xNNy1DNEVsNWp4d2JkWGZmNnhJX0xrM19XMUFkSW1SRDVMTXgwWFJ6X1ZQR24wS0NWeWlaa010SmNSekhGVTYtWlJ0QW1EYWpMT1NULVhOVW0yWmRZLXQxOGdBMkM2YjFNbnVTTkpOQ0FOeG5N?oc=5","date":"2026-04-06","type":"pipeline","source":"openPR.com","summary":"Competitive Landscape: Leading Companies and New Entrants in the Topical Drug Delivery Market - openPR.com","headline":"Competitive Landscape: Leading Companies and New Entrants in the Topical Drug Delivery Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxQdTY3UUVUd2U2T0hxQkNrb1l0UWFnTVI2SXRlbWV3T2xGMDUxakZIcklqTENhSjR2S3NXRlZCdlhrNlFKaTlBZldMZmc3VTZZbFhrUTBIYlg0aG9GeUttMkttUktVSmRLOHp1Vm1XSzdRWWVqaThQdnctX3l2WkJSWTU5MWxnUHYzcFFGY3JtSDMyQ09nWG1BcFBxLTY2NV9kaDJMVXV5WmZNZ2FZNEJmOXVmQVJTd25SdFJxYjI5Z01mbXZHSXZLbDN2Z3RxcURob1gyVW5SSVp1Z3lXczdrak5tTlJsbm9VY2RQZHJkVHpTNEZNX3c?oc=5","date":"2025-10-07","type":"pipeline","source":"PR Newswire","summary":"AHR Agonists Market Trends Signal Promising Growth in Immunology and Dermatology Therapeutics | DelveInsight - PR Newswire","headline":"AHR Agonists Market Trends Signal Promising Growth in Immunology and Dermatology Therapeutics | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxQMkFqR3R5Mmw4WWdUTWVvN0xYM3R4YjVta1RrN0hZSnlNci02aHUtM2FVWEY3TXB2bDk2bEU5Sy1FOVZBZ0JScmtLdjZMc2lfMU9WNVIxblVBSkt2ZGFrNjVsdVNoU0RoS1o0MU9wNnh3RU84ZFJYWVFld1NmY3l2UmtRNnhJdFVpbnNneGhlQWwyNnpKa1Fyak1wVmNiTVgzUjNPdFhLZ0xIZF9FclItdmt0cG02UlVGM1pSdWEtZ2NZTUZWMEYySlJSbk82R090X0ZaZWw0dzluYVhkS3kzTXJTZTBySmJHNXFIcWF4QUNrQXY0UW9ROVhwaVVjTDFUUEhFMHAtaldMemhHTC1kOUVKRmZnRWFKaXZoRm1hOA?oc=5","date":"2025-08-14","type":"trial","source":"GlobeNewswire","summary":"Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma - GlobeNewswire","headline":"Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxONVlMeXBleHo0RFNGcnh1UXF4Skx6c2ZrRkxQdFpmU1h3b3BJS0xGaWNMTUFldkxzaTlnSG1ZdUpPVWxOODJGenNidW5IXzUyTm5ualpHZGU1aFNhMHpIT2h0dXJIY1pubTM3OGZObEVvRkxrUEVZVk94aGFDNkZfbjJ3blVCeVJ5ck5maUZWWjQyRGNBMkgtTzNnYUh6RmlXSk41WFdaZXFuU1paQUE5b3hxYVZvX1h4UFVyd2xWSQ?oc=5","date":"2024-09-18","type":"deal","source":"Fierce Pharma","summary":"Organon pays up to $1.2B to acquire Dermavant and its steroid-free skin cream Vtama - Fierce Pharma","headline":"Organon pays up to $1.2B to acquire Dermavant and its steroid-free skin cream Vtama","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE5rT0E3bENBbFN5Z0d5d3FPV0plMTZURHBleDZ3dkEyY1RwOXJSVGxjX1ByUDhqRHRfY1JJdjdaZF9UX05ZQXRITlNMNlhyUXVYZ3BwX3hQem1fY0FuRGhBNkJaVnVxUQ?oc=5","date":"2024-09-18","type":"pipeline","source":"Reuters","summary":"Dermavant Sciences Ltd. - Reuters","headline":"Dermavant Sciences Ltd.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE1wVVdHR0k5SUpxbEtnS1o4NUVsQzloMVR3dk40Vl9janllRlpRTEdwRVMxQUpDMXljN25fQV9KMUc0UDZwV29yR1JDU25hYTdhWTRfeEhXd21JaWZMZXVOQlFlWkVaRkc5N3c?oc=5","date":"2022-11-14","type":"pipeline","source":"Wiley Online Library","summary":"Journal of the European Academy of Dermatology and Venereology - Wiley Online Library","headline":"Journal of the European Academy of Dermatology and Venereology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPcElza1kxb1VsY01EQmNfYTFZZ09KVjhTdVhsaVZLVkVGREtRdTM4NnpIY2EzNEM0QmcyY2hRR2tvS3BHZF81MFdUTHFybTYtLUpidm0wVVdFQkw5aEtVRUpxZE1KWmsyUUg5Wi1fUE5jbkdiVVVxa3BkdXc5emZTQ01LcXVhM250UGo5a2RVdlo4U29IY3A1b0VWQ3BISlhkS0JBZE44bVBGOF91VFFpMWFpODJ1dw?oc=5","date":"2022-06-29","type":"trial","source":"PMLiVE","summary":"Dermavant publishes positive phase 3 data for treatment of plaque psoriasis - PMLiVE","headline":"Dermavant publishes positive phase 3 data for treatment of plaque psoriasis","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPWndnMk9XRXRORW0tTTVYdktvT3k1NlhzaW81Y3NsbUREaXpyVDUyNVgxUlVJWXV5OU1GUUdfRDNyejFPMkk3aENWUVQ5SmMwdmp6enBNTU8walZ6SThFWkdOV0RJQkNHZDQ5SG85Uk9UT21aSDk3U3Q5YndPOWV3SzJCdzlrSG0yRkRIdFkyajZ4WVdPcWZBU3BYTERPYS15?oc=5","date":"2022-05-27","type":"regulatory","source":"PMLiVE","summary":"Dermavant’s Vtama receives FDA approval for plaque psoriasis - PMLiVE","headline":"Dermavant’s Vtama receives FDA approval for plaque psoriasis","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNbWFaZFIxXzdqdWRpTXZaOXZpNW00bnF6azJXRmpwdnNDcmVieDl2eERhQkR2cDhBUUMyS09YQm1QOXJwclFPdkdVemRQVERiVThpWDQzbHdvLVp5cDdsd2wxZ1lQaXlVTTVER2UyakFVMERHUHVXbXBaWDE3X2hNS2NKZDMzeFU5NXZsQkp1WVlVS3F1UFl1X0ZGMW9FQjU3Tlh2dGtKNVQ2NWFzLVRkS3dDNGkxbm95cHBWdkViSQ?oc=5","date":"2021-01-25","type":"pipeline","source":"Fierce Biotech","summary":"After selling off a clutch of Vants, Roivant CEO Ramaswamy moves upstairs to executive chair - Fierce Biotech","headline":"After selling off a clutch of Vants, Roivant CEO Ramaswamy moves upstairs to executive chair","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}